MedTrace Logo

Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis

NCT07113366 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-08

No results posted yet for this study

Summary

The study is designed to evaluate the efficacy and safety of a topical formulation containing Ficus awkeotsang Makino extract (FAE), derived from jelly fig, in participants with mild to moderate atopic dermatitis. Ficus awkeotsang is a traditional plant native to Taiwan.

Conditions

  • Atopic Dermatitis (AD)

Interventions

DRUG

FAE cream

Ficus awkeotsang Makino extract (FAE)

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Kaohsiung Veterans General Hospital.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2024-06-01
Completion
2024-11-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07113366 on ClinicalTrials.gov